Kolexia
Krhili Samar
Oncologie radiothérapie
Selarl Orlam
Mâcon, France
50 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Récidive tumorale locale Carcinome épidermoïde de la tête et du cou Tumeurs de la prostate Carcinome épidermoïde Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Tumeurs de la tête et du cou

Industries

Ipsen
3 collaboration(s)
Dernière en 2021
Janssen
3 collaboration(s)
Dernière en 2020
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Predictors of toxicity after curative reirradiation with intensity modulated radiotherapy or proton therapy for recurrent head and neck carcinoma: new dose constraints for pharyngeal constrictors muscles and oral cavity.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]   31 mai 2023
Dose-escalation in prostate cancer: Results of randomized trials.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   24 août 2022
Curative high-dose reirradiation for patients with recurrent head and neck squamous cell carcinoma using IMRT or proton therapy: Outcomes and analysis of patterns of failure.
Head & neck   25 juillet 2022
Phase I Study of Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients
2021 Proceedings of the ASTRO 63rd Annual Meeting   01 novembre 2021
The role of proton therapy in esophageal cancer.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   20 octobre 2021
Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Cancer biology & medicine   10 septembre 2021
Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.
2021 ASCO Annual Meeting I   28 mai 2021
Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   18 janvier 2021
Prostate cancer: Usefulness of 18F-fluciclovine PET/CT in the detection and differential diagnosis of an early bone metastasis for successful treatment with radio-guided stereotactic ablative radiotherapy
Revista espanola de medicina nuclear e imagen molecular   01 septembre 2020
Phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.
2020 ASCO Annual Meeting I   25 mai 2020